title: Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.
authors.affiliation: Chief Executive Officer & Managing Director, Spinifex Pharmaceuticals, Victoria, Australia.
authors.forename: T
authors.initials: T
authors.lastname: McCarthy
mesh_terms: D000284:Administration, Oral; D057912:Angiotensin II Type 2 Receptor Blockers / Q000008:administration & dosage*; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage*; D008297:Male; D015337:Multicenter Studies as Topic; D051474:Neuralgia, Postherpetic / Q000188:drug therapy*; D010147:Pain Measurement
chemical_list: D057912:Angiotensin II Type 2 Receptor Blockers; D001559:Benzhydryl Compounds; C000595242:EMA400; D007546:Isoquinolines